

Biographical sketch CIRO ISIDORO



Name CIRO ISIDORO

Email ciro.isidoro@med.uniupo.it

Full Professor of General Pathology and Clinical Pathology

Qualified Full Professor of Clinical Biochemistry and Clinical Molecular Biology

Qualified Full Professor of Medical Oncology

Affiliation Università del Piemonte Orientale, Department of Health Sciences; via Paolo Solaroli 17 – 28100, Novara (Italy)

Website: <http://www.isidorolab.com/>
<https://upobook.uniupo.it/ciro.isidoro@med>

Education:

1983 – Laurea *Summa cum Laude* - Doctor in Biological Sciences (D.Sc.), Università di Torino (Italy)

1984 – National License for Board of Doctor Biologists

1999 - Laurea *Summa cum Laude* - Doctor in Medicine and Surgery (M.D.), Università del Piemonte Orientale (Novara, Italy)

2000 – National License for Board of Medical Doctors and Surgeons.

Representative Careers and affiliations:

2023: TOP 2% Scientist in the world based on scientific production in 2022.

1983-1986: post-lauream fellow at Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Italy)

1986-1989: PhD fellow (Rerum Medicinalis) - Wissenschaftliche Hilfskraft (Assistant Researcher) - Institut fuer Pathobiochemie, Westfaelisch Wilhelms Universitaet Muenster (Germany); from 15.02.1989 through 31.03.1990.

1989-1992: Post-doc-Assistant Researcher at Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Italy)

1993-1999: Assistant Professor of General Pathology, University of Turin (Italy)

2000 to 2019: Associate Professor of Cell Pathology and of Experimental Oncology, School of Medicine, Università del Piemonte Orientale (Novara, Italy).

2000-2000: Visiting Professor at Institute fuer Physiologische Chemie (Prof. A. Hasilik), Klinikum der Philipps-Universität Marburg (D)

2002-2005: Visiting Professor at Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol (UK).

2005 to date: overseas advisor of PhD students at Mahidol University, at Chulalongkorn University, Bangkok; at Khon Kaen University (Thailand)

2013-2020: Visiting Professor, Siriraj Faculty of Medicine, Mahidol University of Bangkok (Thailand).

2016 to present: Visiting Professor, Department of Cell Biology, Oklahoma University Health Science Center (OKC, US).

2018 to 2019: Visiting Professor, Faculty of Allied Health Sciences, Chulalongkorn University of Bangkok (Thailand).

2019-2020: Visiting Professor, University of Bourgogne Franche-Comté, Besancon (France)

2019 to date: Full Professor of General Pathology, Cell Pathology and Experimental Oncology, School of Medicine, Università del Piemonte Orientale (Novara, Italy).

Biographical sketch CIRO ISIDORO

2019-2020 Adjunct Professor Dept of Medicine, College of Medicine, Seoul National University, Seoul (South Korea)

2019-2020: Adjunct Professor Medical Research Institute, Tokyo Medical and Dental University, Tokyo (Japan)

2020-present: Adjunct Professor Siriraj Hospital-Faculty of Medicine, Mahidol University, Bangkok (Thailand)

Representative Awards:

2023: TOP 2% Best Scientists in the World among 8.5 million

2014: *Professor Honoris Causa Faculty of Medicine and Pharmacy, Université de Bourgogne & Franche-Comté of Besançon (France).*

2015: member of the Scientific board of « Integrative Cancer Research Center of the Georgia Institute of Technology », Georgia Tech University, Georgia (Atlanta, US) <https://icrc.gatech.edu/people/Ciro-Isidoro>; <https://icrc.gatech.edu/user/299>

2015: Executive Vice-President of the International Association of Traditional and Complementary Medicine.

2018: Full member of the World Academy of Sciences <http://www.worldacademyofsciences.com/members.html>

EDITORIAL BOARD

Editor-in-Chief of J of Cancer and Metastasis Treatment (2024 to date); J Traditional and Complementary Medicine (2014-2024); Biomedicines (Advisor board member)

Associate Editor of Autophagy, J Translational Medicine, Cancers, Cells, Int J Molecul. Sci, Molecular Carcinogenesis, Frontiers in Oncology, Oncology Lett, Oncology Res, Exptl. & Therap. Medicine, (others)

Research Areas: Role and Regulation of Autophagy in Cancer and in Neurodegeneration. Epigenetic regulation of Autophagy and cell death. Anti-aging and anti-cancer Nutraceuticals. Organelle biogenesis, vesicular traffic, and diseases. Nanotheranostics ('in cellulo' imaging). Omics technology in human diseases diagnosis and therapy. Molecular and pathophysiological mechanisms of COVID-19 and of COVID19 vaccine's adverse effects.

International Patent (C. Follo e C. Isidoro), PCT No. WO2008/065505 (5-06-2008).

LINK: <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2008065505&redirectedID=true>

Bibliometric index:

Scopus H Index = 55; citations >10.000

Google Scholar H Index = 57; citations >34.000

Google Scholar personal webpage <https://scholar.google.it/citations?hl=it&user=YaKkwGMAAAAJ>

Total Impact Factor >1250

ORCID <https://orcid.org/0000-0002-5494-3034>

Publications 199 full articles in peer-review journals plus 16 chapters/books.

PUBMED <https://www.ncbi.nlm.nih.gov/pubmed/?term=isidoro+c>

INTERNATIONAL SCIENTIFIC SOCIETY MEMBERSHIP

- International Society of Precision Cancer Medicine (founder member, since Apr 2018)
- International Association of Traditional and Complementary Medicine (Executive Vice President, since Nov 2015)
- International Proteolysis Society (founder member, since 1999)
- Associazione Italiana di Biologia Cellulare e del Differenziamento (ABCD) (founder member)
- Italian Society of Cancerology
- European Cancer Society
- European Cell Biology Society


TOP 2% Scientist in the world based on quality of scientific production in 2022.

Prof. Ciro Isidoro ranks 157259 among 8.5 million scientists in the world.

A bibliometric study performed by Prof. J. Ioannidis's team at Stanford University has considered the quantity, quality, and diffusion of publications within the scientific community and elaborated standardized information on citations, h-index, co-authorship adjusted hm-index, citations to papers in different authorship positions and a composite indicator (c-score). The authors analyzed data relating to over 8 and a half million researchers from universities and research centers throughout the world. Among them, approximately **195,000 scientists stood out for their scientific authority and currently represent the best 2%.** **In this ranking, Prof. Ciro Isidoro is n. 157259.**

<https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/6>

https://drive.google.com/file/d/1ro19angG6WqVA5zX9vUISegw38QLQok0/view?usp=drive_web



Best Biology and Biochemistry Scientists in Italy

The 4th edition of Research.com ranking of the best scholars in the field of Biology and Biochemistry was created using data combined from a wide range of data sources including OpenAlex and CrossRef. The bibliometric data for devising the citation-based metrics were acquired on 27-11-2024. Position in the ranking is based on a scholar's D-index (Discipline H-index), which only includes papers and citation values for an examined discipline.

[Show more](#)

Ciro Isidoro		Italy (582)				
World	National	Scholar		D-Index	Citations	Publications
13091	402		Ciro Isidoro University of Eastern Piedmont Amadeo Avogadro, Italy	54	36,068	205

<https://research.com/scientists-rankings/biology-and-biochemistry/it?page=5>

Biographical sketch CIRO ISIDORO

TOP ITALIAN SCIENTIST IN BIOMEDICAL SCIENCES

<https://topitalianscientists.org/top-italian-scientists-scopus/Biomedical%20Sciences/1>

Ciro Isidoro - Top Italian Scientist in Biomedical Sciences

Human Pathology Cancer Neurodegeneration Autophagy Lysosomes Cell death Complementary Medicine



Rank: 1337

H-Index: 50

Citations: 23868

Nation: Italy

Area: cancer - medicine

Macroarea: Biomedical Sciences

Italian Institution(s): Università degli Studi del Piemonte Orientale "Amedeo Avogadro"

CODICE FISCALE SDRCRI56M29Z326U;

"Ai sensi del GDPR (2016/679) e della normativa vigente in materia di privacy autorizzo il trattamento dei miei dati personali. Dichiaro, inoltre, che ogni informazione espressa nel presente Curriculum Vitae corrisponde a verità".

Autorizzo e consento il trattamento dei miei dati personali ai sensi dell'art. 13 del D.Lgs. 196/03 e dell'art. 13 GDPR 679/16 e Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Novara, January 23rd, 2026

MOST RECENT SELECTED PUBLICATIONS (2024 to December 2025)

199. Isidoro, C. SARS-CoV2 and Anti-COVID-19 mRNA Vaccines: Is There a Plausible Mechanistic Link with Cancer? *Cancers* 2025, 17, 3867. <https://doi.org/10.3390/cancers17233867>
198. Nadhan R, Nath K, Basu S, Isidoro C, Song YS, Dhanasekaran DN. Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks. *Signal Transduct Target Ther.* 2025 Oct 10;10(1):337. doi: 10.1038/s41392-025-02423-4. PMID: 41068071; PMCID: PMC12511386.
197. Garavaglia B, Ferraresi A, Vidoni C, Vallino L, Lualdi C, Mollace V, Isidoro C. Butyrate and Resveratrol synergize to inhibit colorectal cancer cell proliferation and migration by preventing the nuclear translocation of β -catenin. *BIO Web of Conferences* 187, 04001 (2025) ISPH-ISNPR 2025, <https://doi.org/10.1051/bioconf/202518704001>
196. Maheshwari, C.; Castiglioni, A.; Walusimbi, U.; Vidoni, C.; Ferraresi, A.; Dhanasekaran, D.N.; Isidoro, C. The Biological Role and Clinical Significance of BECLIN-1 in Cancer. *Int. J. Mol. Sci.* 2025, 26, 9380. <https://doi.org/10.3390/ijms26199380>
195. Garavaglia B, Vallino L, Ferraresi A, Visciglia A, Amoruso A, Pane M, Munteanu C, Isidoro C. The Anti-Inflammatory, Immunomodulatory, and Pro-Autophagy Activities of Probiotics for Colorectal Cancer Prevention and Treatment: A Narrative Review. *Biomedicines.* 2025 Jun 25;13(7):1554. doi: 10.3390/biomedicines13071554. PMID: 40722631; PMCID: PMC12293081.
194. Ferraresi A, Ghezzi I, Salwa A, Lualdi C, Dhanasekaran DN, Isidoro C. P53-Induced Autophagy Degradation of NKX3-2 Improves Ovarian Cancer Prognosis. *Cells.* 2025; 14(11):765. <https://doi.org/10.3390/cells14110765>.
193. Bonetto V, Ferraresi A, Sampò S, Isidoro C. Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders. *Int J Mol Sci.* 2025 May 16;26(10):4800. doi: 10.3390/ijms26104800.
192. Garavaglia B, Vallino L, Ferraresi A, Amoruso A, Pane M, Isidoro C. Probiotic-Derived Metabolites from *Lactiplantibacillus plantarum* OC01 Reprogram Tumor-Associated Macrophages to an Inflammatory Anti-Tumoral Phenotype: Impact on Colorectal Cancer Cell Proliferation and Migration. *Biomedicines.* 2025 Feb 3;13(2):339. doi: 10.3390/biomedicines13020339. PMID: 40002754; PMCID: PMC11853712.
191. Bellavite P, Donzelli A, Isidoro C. The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement. *J Clin Med.* 2024 Nov 30;13(23):7291. doi: 10.3390/jcm13237291. PMID: 39685749; PMCID: PMC11642405.
190. Beatrice Garavaglia, Letizia Vallino, Angela Amoruso, Marco Pane, Alessandra Ferraresi, Ciro Isidoro, The role of gut microbiota, immune system, and autophagy in the pathogenesis of inflammatory bowel disease: Molecular mechanisms and therapeutic approaches. *Aspects of Molecular Medicine*, Volume 4, 2024, 100056, <https://doi.org/10.1016/j.amolm.2024.100056>.
189. Nadhan R, Isidoro C, Song YS, Dhanasekaran DN. LncRNAs and the cancer epigenome: Mechanisms and therapeutic potential. *Cancer Lett.* 2024 Nov 28;605:217297. doi: 10.1016/j.canlet.2024.217297. Epub 2024 Oct 16. PMID: 39424260.
188. Isidoro C, Ntanas-Stathopoulos I. Editorial: Understanding patient nutrition and cancer progression. *Front Oncol.* 2024 Nov 25;14:1518083. doi: 10.3389/fonc.2024.1518083. PMID: 39655074; PMCID: PMC11625663.
187. Ferraresi A, Ghezzi I, Salwa A, Esposito A, Dhanasekaran DN, Isidoro C. NKX3-2 Induces Ovarian Cancer Cell Migration by HDAC6-Mediated Repositioning of Lysosomes and Inhibition of Autophagy. *Cells.* 2024 Nov 4;13(21):1816. doi: 10.3390/cells13211816. PMID: 39513923; PMCID: PMC11544992.

Biographical sketch CIRO ISIDORO

186. Salwa A, Ferraresi A, Vallino L, Maheshwari C, Moia R, Gaidano G, Isidoro C. High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias. *Int J Mol Sci.* 2024 Oct 27;25(21):11527. doi: 10.3390/ijms252111527. PMID: 39519080; PMCID: PMC11546612.
185. Esposito A, Ferraresi A, Vallino L, Garavaglia B, Dhanasekaran DN, Isidoro C. Three-Dimensional In Vitro Cell Cultures as a Feasible and Promising Alternative to Two-Dimensional and Animal Models in Cancer Research. *Int J Biol Sci.* 2024 Sep 30;20(13):5293-5311. doi: 10.7150/ijbs.96469. PMID: 39430243; PMCID: PMC11488579.
184. Ferraresi A, Girone C, Maheshwari C, Vallino L, Dhanasekaran DN, Isidoro C. Ovarian Cancer Cell-Conditioning Medium Induces Cancer-Associated Fibroblast Phenocconversion through Glucose-Dependent Inhibition of Autophagy. *International Journal of Molecular Sciences.* 2024; 25(11):5691. <https://doi.org/10.3390/ijms25115691>
183. Ha JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, Jayaraman M, Yan M, Kashyap S, Fung KM, Xu C, Bhattacharya R, Mukherjee P, Isidoro C, Song YS, Dhanasekaran DN. Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer. *Cancer Lett.* 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891. Epub ahead of print. PMID: 38642607.
182. Secomandi, E.; Esposito, A.; Camurani, G.; Vidoni, C.; Salwa, A.; Lualdi, C.; Vallino, L.; Ferraresi, A.; Isidoro, C. Differential Competitive Growth of Transgenic Subclones of Neuroblastoma Cells Expressing Different Levels of Cathepsin D Co-Cultured in 2D and 3D in Response to EGF: Implications in Tumor Heterogeneity and Metastasis. *Cancers* **2024**, *16*, 1343. <https://doi.org/10.3390/cancers16071343>
181. Sillapachaiyaporn C, Wongwan C, Mongkolpobsin K, Nilkhet S, Isidoro C, Chuchawankul S, Tencomnao T. Ergosterol promotes neurite outgrowth, inhibits amyloid-beta synthesis, and extends longevity: In vitro neuroblastoma and in vivo *Caenorhabditis elegans* evidence. *Life Sci.* 2024 Apr 2:122606. doi: 10.1016/j.lfs.2024.122606. Epub ahead of print. PMID: 38574884.
180. Ferraresi A, Thongchot S, Isidoro C. Resveratrol Promotes Self-digestion to Put Cancer to Sleep. *J Cancer Prev.* 2024 Mar 30;29(1):1-5. doi: 10.15430/JCP.24.001. Epub 2024 Mar 29. PMID: 38567110; PMCID: PMC10982519.
179. Chen X, Tsvetkov AS, Shen HM, Isidoro C, Ktistakis NT, Linkermann A, Koopman WJH, Simon HU, Galluzzi L, Luo S, Xu D, Gu W, Peulen O, Cai Q, Rubinsztein DC, Chi JT, Zhang DD, Li C, Toyokuni S, Liu J, Roh JL, Dai E, Juhasz G, Liu W, Zhang J, Yang M, Liu J, Zhu LQ, Zou W, Piacentini M, Ding WX, Yue Z, Xie Y, Petersen M, Gewirtz DA, Mandell MA, Chu CT, Sinha D, Eftekharpour E, Zhivotovsky B, Besteiro S, Gabrilovich DI, Kim DH, Kagan VE, Bayir H, Chen GC, Ayton S, Lünemann JD, Komatsu M, Krautwald S, Loos B, Baehrecke EH, Wang J, Lane JD, Sadoshima J, Yang WS, Gao M, Münz C, Thumm M, Kampmann M, Yu D, Lipinski MM, Jones JW, Jiang X, Zeh HJ, Kang R, Klionsky DJ, Kroemer G, Tang D. International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis. *Autophagy.* 2024 Mar 5. doi: 10.1080/15548627.2024.2319901. Epub ahead of print. PMID: 38442890.
178. Thongchot S, Ferraresi A, Vidoni C, Salwa A, Vallino L, Kittirat Y, Loilome W, Namwat N, Isidoro C. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis. *Cancer Lett.* 2024 Feb 1;582:216589. doi: 10.1016/j.canlet.2023.216589. Epub 2023 Dec 12. PMID: 38097133.